Literature DB >> 12973165

Inflammatory status in sepsis alters efficacy of interleukin-18 binding protein therapy.

Daniel G Remick1, Gerald E Bolgos, Javed Siddiqui.   

Abstract

OBJECTIVE: Sepsis remains a serious clinical problem, and multiple attempts at blocking inflammation have failed to decrease mortality rate. Interleukin-18 has been demonstrated to be an important component of the innate immune response to bacterial infections.
DESIGN: Previous work demonstrated that elevated plasma concentrations of interleukin-6 obtained in the first 6 hrs of sepsis predict a worse outcome. Mice were subjected to cecal ligation and puncture and, on the basis of the plasma concentration of interleukin-6, were randomized to receive either interleukin-18 binding protein or vehicle approximately 8 hrs after the onset of sepsis.
SETTING: University research laboratory.
SUBJECTS: Adult, female BALB/c mice.
INTERVENTIONS: We sought to determine the role of interleukin-18 in sepsis by blocking its biological activity with the interleukin-18 binding protein in the murine model of sepsis induced by cecal ligation and puncture.
MEASUREMENTS AND MAIN RESULTS: In this study, elevated plasma concentrations of interleukin-6 were associated with a worse outcome. Treatment with interleukin-18 binding protein decreased inflammation as determined by lower concentrations of plasma interleukin-6 obtained 48 hrs after the onset of sepsis. In mice with increased risk of dying, interleukin-18 binding protein slightly decreased mortality rate. However, in those mice with a predicted low mortality rate, interleukin-18 binding protein significantly increased mortality rate.
CONCLUSIONS: In this study, mice at low risk of death due to sepsis had decreased survival when treated with interleukin-18 binding protein. These results have potential implications for the use of interleukin-18 binding protein for treatment of chronic inflammatory conditions since it may place the host at increased risk of infectious complications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12973165     DOI: 10.1097/01.CCM.0000080492.81509.29

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  7 in total

Review 1.  Modeling sepsis in the laboratory: merging sound science with animal well-being.

Authors:  Jean A Nemzek; Kelly M S Hugunin; Mark R Opp
Journal:  Comp Med       Date:  2008-04       Impact factor: 0.982

2.  Role of interleukin-6 in mortality from and physiologic response to sepsis.

Authors:  Daniel G Remick; Gerald Bolgos; Shannon Copeland; Javed Siddiqui
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

Review 3.  Pathophysiology of sepsis.

Authors:  Daniel G Remick
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

4.  Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.

Authors:  Kendra N Iskander; Marcin F Osuchowski; Deborah J Stearns-Kurosawa; Shinichiro Kurosawa; David Stepien; Catherine Valentine; Daniel G Remick
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

5.  Endogenous interleukin-18 improves the early antimicrobial host response in severe melioidosis.

Authors:  W Joost Wiersinga; Catharina W Wieland; Gerritje J W van der Windt; Anita de Boer; Sandrine Florquin; Arjen Dondorp; Nicholas P Day; Sharon J Peacock; Tom van der Poll
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

6.  Stratification to predict the response to antioxidant.

Authors:  Cristiane Ritter; Larissa Constantino; Monique Michels; Renata Casagrande Gonçalves; Cassiana Fraga; Danusa Damásio; Felipe Dal-Pizzol
Journal:  Rev Bras Ter Intensiva       Date:  2020-05-08

Review 7.  Interleukin-18: Biological properties and role in disease pathogenesis.

Authors:  Gilles Kaplanski
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.